Prescribing The Future: How MangoRx Is Shaking Up Telemedicine With A Fresh Platform - Mangoceuticals ( NASDAQ:MGRX ) , Hims & Hers Health ( NYSE:HIMS )
Since Covid-19, telemedicine has been expanding significantly, with 44% of physicians using it at least weekly and 40% daily in the U.S. in 2023. The industry is seen by some as a new frontier for patient education and access to medicine and care.
| Ticker |
Sentiment |
Impact |
|
MGRX
|
Somewhat Bullish
|
11 %
|
|
HIMS
|
Neutral
|
11 %
|
